Reshma L. Mahtani DO
Chief of Breast Medical Oncology, Miami Cancer Institute, Baptist Health South Florida
- Board member since 2023
- Medical Advisory Board member
- Medical oncologist and clinical researcher focusing on new therapies for breast cancer
- Serves on the editorial board of The Breast Journal
Reshma L. Mahtani, DO, is a medical oncologist practicing in South Florida. She is the chief of breast medical oncology at the Miami Cancer Institute at Baptist Health South Florida, which is a member of the Memorial Sloan Kettering Alliance.
Dr. Mahtani is committed to medical education. She speaks nationally and internationally and has served as program director for several officially licensed Best of ASCO programs for the American Society of Clinical Oncology. She is an active clinical researcher and her research focuses on novel therapies for the treatment of breast cancer.
While at Sylvester Comprehensive Cancer Center, she oversaw the clinical trial program across the network. She has also served on the ASCO Quality Oncology Practice Initiative Steering Committee and is a member of the editorial board of The Breast Journal.
She is honored to join LBBC’s Board of Directors. She is committed to medical education and has been involved in educating both providers and patients. Keenly aware of the key role that education plays in improving patient outcomes, she has been involved in several initiatives that have helped patients make informed decisions about their health.
While some breast cancers express hormone receptors or have too many copies of the HER2 gene, other breast cancers may not have these characteristics. Triple-negative breast cancers (TNBC) do not express estrogen receptors, progesterone receptors, or HER2 receptors. About 10% to 15% of breast cancers are triple-negative.
Breast cancer treatment during the coronavirus outbreak
Drs. Julie Gralow and Reshma Mahtani explain how people in treatment for breast cancer can balance the known threat of breast cancer against what was known about the potential threat of developing COVID-19 in the first few months of the pandemic.